Tumor expression of S100A6 correlates with survival of patients with stage I non-small-cell lung cancer

Lung Cancer

Volumn 63, Issue 3, 2009, Pages 410-417

  De Petris, Luigi ^a   Orre, Lukas M ^a   Kanter, Lena ^b   Pernemalm, Maria ^a   Koyi, Hirsh ^b   Lewensohn, Rolf ^a   Lehtiö, Janne ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Immunohistochemistry; NSCLC; Proteomics; S100A4; S100A6; SELDI TOF MS; Tissue microarray

Indexed keywords

CALCYCLIN; CALVASCULIN; PROTEIN P53;

ADULT; AGED; ARTICLE; CANCER CELL CULTURE; CANCER PATIENT; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CELL LYSATE; CLINICAL ARTICLE; FEMALE; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MALE; MICROARRAY ANALYSIS; MULTIVARIATE ANALYSIS; PLEURA EFFUSION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; PROTEIN SYNTHESIS REGULATION; SURFACE ENHANCED LASER DESORPTION IONIZATION TIME OF FLIGHT MASS SPECTROMETRY; TISSUE MICROARRAY;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA, NON-SMALL-CELL LUNG; CELL CYCLE PROTEINS; DNA, NEOPLASM; EPIDERMAL GROWTH FACTOR; FEMALE; FOLLOW-UP STUDIES; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PROGNOSIS; S100 PROTEINS; SURVIVAL RATE; SWEDEN;

EID: 59449102963     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2008.06.003     Document Type: Article

References (40)

1. Parkin D.M., Bray F., Ferlay J., and Pisani P. Global cancer statistics 2002. CA Cancer J Clin 55 (2005) 74-108
2. Pignon J.P., Tribodet H., Scagliotti G.V., Douillard J.Y., Shepherd F.A., Stephens R.J., et al. Lung Adjuvant Cisplatin Evaluation (LACE): a pooled analysis of five randomized clinical trials including 4584 patients. J Clin Oncol 24 (2006) 7008 Abstract
3. Emberley E.D., Murphy L.C., and Watson P.H. S100 proteins and their influence on pro-survival pathways in cancer. Biochem Cell Biol 82 (2004) 508-515
4. Santamaria-Kisiel L., Rintala-Dempsey A.C., and Shaw G.S. Calcium-dependent and -independent interactions of the S100 protein family. Biochem J 396 (2006) 201-214
5. Orre L.M., Pernemalm M., Lengqvist J., Lewensohn R., and Lehtio J. Up-regulation, modification and translocation of S100A6 induced by exposure to ionizing radiation, revealed by proteomic profiling. Mol Cell Proteomics 6 (2007) 2122-2131
6. Forsberg L., Larsson C., Sofiadis A., Lewensohn R., Hoog A., and Lehtio J. Pre-fractionation of archival frozen tumours for proteomics applications. J Biotechnol 126 (2006) 582-586
7. Kallioniemi O.P., Wagner U., Kononen J., and Sauter G. Tissue microarray technology for high-throughput molecular profiling of cancer. Hum Mol Genet 10 (2001) 657-662
8. Mitsudomi T., Oyama T., Nishida K., Ogami A., Osaki T., Nakanishi R., et al. p53 nuclear immunostaining and gene mutations in non-small-cell lung cancer and their effects on patient survival. Ann Oncol 6 Suppl. 3 (1995) S9-13
9. Kimura K., Endo Y., Yonemura Y., Heizmann C.W., Schafer B.W., Watanabe Y., et al. Clinical significance of S100A4 and E-cadherin-related adhesion molecules in non-small cell lung cancer. Int J Oncol 16 (2000) 1125-1131
10. Vimalachandran D., Greenhalf W., Thompson C., Luttges J., Prime W., Campbell F., et al. High nuclear S100A6 (calcyclin) is significantly associated with poor survival in pancreatic cancer patients. Cancer Res 65 (2005) 3218-3225
11. Matsubara D., Niki T., Ishikawa S., Goto A., Ohara E., Yokomizo T., et al. Differential expression of S100A2 and S100A4 in lung adenocarcinomas: clinicopathological significance, relationship to p53 and identification of their target genes. Cancer Sci 96 (2005) 844-857
12. Leclerc E., Fritz G., Weibel M., Heizmann C.W., and Galichet A. S100b and S100A6 differentially modulate cell survival by interacting with distinct RAGE (receptor for advanced glycation end products) immunoglobulin domains. J Biol Chem 282 (2007) 31317-31331
13. Soussi T. p53 alterations in human cancer: more questions than answers. Oncogene 26 (2007) 2145-2156
14. Joo J.H., Yoon S.Y., Kim J.H., Paik S.G., Min S.R., Lim J.S., et al. S100A6 (calcyclin) enhances the sensitivity to apoptosis via the upregulation of caspase-3 activity in Hep3B cells. J Cell Biochem (2007)
15. Luu H.H., Zhou L., Haydon R.C., Deyrup A.T., Montag A.G., Huo D., et al. Increased expression of S100A6 is associated with decreased metastasis and inhibition of cell migration and anchorage independent growth in human osteosarcoma. Cancer Lett 229 (2005) 135-148
16. Mitsudomi T., Hamajima N., Ogawa M., and Takahashi T. Prognostic significance of p53 alterations in patients with non-small cell lung cancer: a meta-analysis. Clin Cancer Res 6 (2000) 4055-4063
17. Kwiatkowski D.J., Harpole Jr. D.H., Godleski J., Herndon J.E., Shieh D.B., Richards W., et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol 16 (1998) 2468-2477
18. Quinlan D.C., Davidson A.G., Summers C.L., Warden H.E., and Doshi H.M. Accumulation of p53 protein correlates with a poor prognosis in human lung cancer. Cancer Res 52 (1992) 4828-4831
19. Tomizawa Y., Kohno T., Fujita T., Kiyama M., Saito R., Noguchi M., et al. Correlation between the status of the p53 gene and survival in patients with stage I non-small cell lung carcinoma. Oncogene 18 (1999) 1007-1014
20. Burke L., Flieder D.B., Guinee D.G., Brambilla E., Freedman A.N., Bennett W.P., et al. Prognostic implications of molecular and immunohistochemical profiles of the Rb and p53 cell cycle regulatory pathways in primary non-small cell lung carcinoma. Clin Cancer Res 11 (2005) 232-241
21. Crnogorac-Jurcevic T., Missiaglia E., Blaveri E., Gangeswaran R., Jones M., Terris B., et al. Molecular alterations in pancreatic carcinoma: expression profiling shows that dysregulated expression of S100 genes is highly prevalent. J Pathol 201 (2003) 63-74
22. Ohuchida K., Mizumoto K., Ishikawa N., Fujii K., Konomi H., Nagai E., et al. The role of S100A6 in pancreatic cancer development and its clinical implication as a diagnostic marker and therapeutic target. Clin Cancer Res 11 (2005) 7785-7793
23. Brown L.M., Helmke S.M., Hunsucker S.W., Netea-Maier R.T., Chiang S.A., Heinz D.E., et al. Quantitative and qualitative differences in protein expression between papillary thyroid carcinoma and normal thyroid tissue. Mol Carcinog 45 (2006) 613-626
24. Ito Y., Yoshida H., Tomoda C., Uruno T., Miya A., Kobayashi K., et al. Expression of S100A2 and S100A6 in thyroid carcinomas. Histopathology 46 (2005) 569-575
25. Komatsu K., Kobune-Fujiwara Y., Andoh A., Ishiguro S., Hunai H., Suzuki N., et al. Increased expression of S100A6 at the invading fronts of the primary lesion and liver metastasis in patients with colorectal adenocarcinoma. Br J Cancer 83 (2000) 769-774
26. Choufani G., Mahillon V., Decaestecker C., Lequeux T., Danguy A., Salmon I., et al. Determination of the levels of expression of sarcolectin and calcyclin and of the percentages of apoptotic but not proliferating cells to enable distinction between recurrent and nonrecurrent cholesteatomas. Laryngoscope 109 (1999) 1825-1831
27. Rehman I., Cross S.S., Azzouzi A.R., Catto J.W., Deloulme J.C., Larre S., et al. S100A6 (Calcyclin) is a prostate basal cell marker absent in prostate cancer and its precursors. Br J Cancer 91 (2004) 739-744
28. Ribe A., and McNutt N.S. S100A6 protein expression is different in Spitz nevi and melanomas. Mod Pathol 16 (2003) 505-511
29. Rehman I., Cross S.S., Catto J.W., Leiblich A., Mukherjee A., Azzouzi A.R., et al. Promoter hyper-methylation of calcium binding proteins S100A6 and S100A2 in human prostate cancer. Prostate 65 (2005) 322-330
30. Helfman D.M., Kim E.J., Lukanidin E., and Grigorian M. The metastasis associated protein S100A4: role in tumour progression and metastasis. Br J Cancer 92 (2005) 1955-1958
31. Miyazaki N., Abe Y., Oida Y., Suemizu H., Nishi M., Yamazaki H., et al. Poor outcome of patients with pulmonary adenocarcinoma showing decreased E-cadherin combined with increased S100A4 expression. Int J Oncol 28 (2006) 1369-1374
32. Wang G., Zhang S., Fernig D.G., Martin-Fernandez M., Rudland P.S., and Barraclough R. Mutually antagonistic actions of S100A4 and S100A1 on normal and metastatic phenotypes. Oncogene 24 (2005) 1445-1454
33. 2+-dependent binding of calcyclin to muscle tropomyosin. Biochem Biophys Res Commun 220 (1996) 360-365
34. Takenaga K., Nakamura Y., Sakiyama S., Hasegawa Y., Sato K., and Endo H. Binding of pEL98 protein, an S100-related calcium-binding protein, to nonmuscle tropomyosin. J Cell Biol 124 (1994) 757-768
35. Bartling B., Rehbein G., Schmitt W.D., Hofmann H.S., Silber R.E., and Simm A. S100A2-S100P expression profile and diagnosis of non-small cell lung carcinoma: impairment by advanced tumour stages and neoadjuvant chemotherapy. Eur J Cancer 43 (2007) 1935-1943
36. Diederichs S., Bulk E., Steffen B., Ji P., Tickenbrock L., Lang K., et al. S100 family members and trypsinogens are predictors of distant metastasis and survival in early-stage non-small cell lung cancer. Cancer Res 64 (2004) 5564-5569
37. Feng G., Xu X., Youssef E.M., and Lotan R. Diminished expression of S100A2, a putative tumor suppressor, at early stage of human lung carcinogenesis. Cancer Res 61 (2001) 7999-8004
38. Smith S.L., Gugger M., Hoban P., Ratschiller D., Watson S.G., Field J.K., et al. S100A2 is strongly expressed in airway basal cells, preneoplastic bronchial lesions and primary non-small cell lung carcinomas. Br J Cancer 91 (2004) 1515-1524
39. Wang H., Zhang Z., Li R., Ang K.K., Zhang H., Caraway N.P., et al. Overexpression of S100A2 protein as a prognostic marker for patients with stage I non small cell lung cancer. Int J Cancer 116 (2005) 285-290
40. Zech V.F., Dlaska M., Tzankov A., and Hilbe W. Prognostic and diagnostic relevance of hnRNP A2/B1, hnRNP B1 and S100 A2 in non-small cell lung cancer. Cancer Detect Prev 30 (2006) 395-402